Beijing-based private equity firm Huagai Capital has led a $146.6-million round in China’s HaiHe Biopharma, which is engaged in the discovery, development and commercialisation of drugs for cancer treatment, according to an official release.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
